Six New Trustees Join Board of Buck Institute

New members include Bay Area civic and business leaders, physicians from Mayo Clinic and Duke University and the Buck’s first international trustee

September 20, 2013, Novato, CA Six new members were appointed to the Buck Institute Board of Trustees today including prominent Bay Area civic and business leaders as well as physicians from Mayo Clinic and Duke University. The Buck also appointed its first international trustee. All will begin three-year terms on January 1, 2014.

Roy Eisenhardt is a civic and business leader in the Bay Area. He started his career at the law firm Farella, Braun & Martel in San Francisco in 1966. He then taught as a visiting professor at the University of California Berkeley Law School. In the 1980’s he became the President of Major League Baseball’s Oakland A’s where he led the team through comprehensive changes. In 1989, Eisenhardt became the Executive Director of the California Academy of Sciences. In 1995, he became a consultant and also began serving on several nonprofit and corporate boards. During the year 2010-2011, he served as Interim President of San Francisco Art Institute. He currently serves as a Trustee of the California Pacific Medical Center Foundation, is a frequent interviewer at City Arts & Lectures, and is a lecturer in law at UC Berkeley. Eisenhardt is a veteran of the US Marines.  

John W. Larson is a retired San Francisco lawyer with over 40 years of practice devoted to high-tech and life science companies. Before his retirement he was a partner at Morgan, Lewis & Bockius, LLP. During the early 1970’s he served as Assistant Secretary in the U.S. Department of the Interior and as Counselor to George Schultz. He currently serves on the Buck Institute’s Technology Transfer Committee. Larson is a long-time resident of Marin County and has held a number of civic posts including chairman of the San Francisco Chamber of Commerce and President of the Branson School. He currently serves on several corporate boards and is Chairman of WageWorks, a NYSE company.

Fouad Makhzoumi is executive chairman and CEO of Future Group, including Future Pipe Industries Group of Dubai, which has over 3,500 employees in 23 countries and is a global leader in anti-corrosive fiberglass pipe system design and manufacturing. It operates in over 50 countries. A Lebanese native, Makhzoumi has a Master’s degree in Chemical Engineering from Michigan Technological University. He has been a member of the International Board of the Council on Foreign Relations: US/Middle East Project (USMEP) and Vice Chairman of the Institute for Social and Economic Policy in the Middle East at the John F. Kennedy School of Government at Harvard University. He was also a member of the Centre for Strategic and International Studies (CSIS) and of the International Council for the Middle East Studies, as well as a member of the International Institute for Strategic Studies and of the Arab Reform Initiative. Makhzoumi is currently a member of the Middle East Board of the S. Olayan Business School at the American University of Beirut. In 1997, he created the Makhzoumi Foundation to help increase the standard of living for underprivileged Lebanese.

Catherine Munson was chair of the Buck Institute Board of Trustees from 2010 to 2012 and is returning after a one-year term away from those duties. She is CEO of LVPMarin Realtors, which provides real estate services for the private and commercial sectors and is involved in development of real estate ventures. She is a Director and Vice Chair of Alta Pacific Bank of Santa Rosa, and has served as a Director of Business Bancorp and Business Bank of California since 2001. Well known as a civic leader in Marin County, she serves on the boards of the Marin Symphony and the Frank Lloyd Wright Civic Center Conservancy. She received a Master’s degree in Microbiology and Biochemistry from the University of Nebraska.

Franklyn Prendergast, MD, PhD, is Professor of Biochemistry & Molecular Biology and Professor of Pharmacology and Experimental Therapeutics at the College of Medicine at Mayo Clinic in Rochester, Minnesota. He is Director Emeritus of the Mayo Clinic Comprehensive Cancer Center and of the Mayo Clinic Center for Individualized Medicine and an Emeritus member of the Mayo Clinic Board of Trustees. Dr. Prendergast’s primary research interests include the structure, dynamics and function of proteins, the biochemistry and biophysics of bioluminescence, and bioimaging. He has served on numerous boards and committees, including those at the Mayo Clinic, the NIH, as well as Eli Lilly where he is currently a director. A Rhodes Scholar, he received his MD from the University of the West Indies and his PhD in Biochemistry from the University of Minnesota, Twin Cities.

Ralph Snyderman, MD, is Chancellor Emeritus at Duke University and James B. Duke Professor of Medicine. He served as Chancellor for Health Affairs and Dean of the School of Medicine from 1989 to 2004. During this time, he oversaw the development of the Duke University Health System, one of the most successful integrated health systems in the country and served as its first CEO and President. He was also a prominent researcher in the field of inflammation and has won many awards for his seminal work on leukocyte chemotaxis. In 1987, Dr. Snyderman joined Genentech, Inc. as vice president for medical research and development where he led the development and licensing of important therapeutics and supervised 300 staff members working in pharmacology, clinical research and regulatory affairs. He served on the board of Proctor and Gamble. He has been called “the father of personalized medicine” by the Association of American Medical Colleges. Dr. Snyderman has authored nearly 400 manuscripts and numerous books and is a member of the Institute of Medicine and the American Academy of Arts & Sciences

About the Buck Institute for Research on Aging
The Buck Institute is the U.S.’s first and foremost independent research organization devoted to Geroscience – focused on the connection between normal aging and chronic disease. Based in Novato, CA, The Buck is dedicated to extending “Healthspan”, the healthy years of human life and does so utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer’s and Parkinson’s, cancer, cardiovascular disease, osteoporosis, macular degeneration, diabetes and stroke.  In their collaborative research, they are supported by the most recent developments in genomics, stem cell technologies, proteomics and bioinformatics. For more information:

Change text size: